INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of North Carolina at Chapel Hill
Chapel Hill, Estados UnidosPublicaciones en colaboración con investigadores/as de University of North Carolina at Chapel Hill (29)
2023
-
Global disparities in patients with multiple myeloma: a rapid evidence assessment
Blood Cancer Journal, Vol. 13, Núm. 1
2022
2021
-
Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study
Journal of Infection, Vol. 83, Núm. 3, pp. 306-313
-
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (Leukemia, (2021), 35, 7, (2119-2124), 10.1038/s41375-021-01125-4)
Leukemia
-
Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit
Schizophrenia Research, Vol. 227, pp. 10-17
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal, Vol. 11, Núm. 12
-
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Leukemia
2020
-
COVID-19, asthma, and biological therapies: What we need to know
World Allergy Organization Journal, Vol. 13, Núm. 5
2018
-
Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases
Cell Death and Differentiation, Vol. 25, Núm. 3, pp. 542-572
2016
-
Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry
Journal of the American Heart Association, Vol. 5, Núm. 10
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial
The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction
Blood, Vol. 128, Núm. 9, pp. 1282-1289
-
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89
2015
-
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Seminars in Cancer Biology, Vol. 35, pp. S276-S304
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477
-
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy
Journal of the National Cancer Institute, Vol. 106, Núm. 11